Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Sea sponge drug could boost advanced breast cancer survival by 5 extra months

03.11.2014

THE cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Monday).

Researchers led by Professor Chris Twelves, based at the University of Leeds and Leeds Teaching Hospitals NHS Trust, looked at two major clinical trials of more than 1,800 women with breast cancer that had started to spread to other parts of the body. The phase III trials – the final stage of testing before deciding whether a drug can be prescribed to patients – compared the survival of women treated with eribulin* to those given standard treatment.

The two studies showed an overall improvement in survival of more than two months for women treated with eribulin**. The most significant improvement was seen in women with the advanced triple negative form of breast cancer, where there are limited treatment options; these women's survival improved by nearly five months. There was also a survival boost of more than two months for women with the HER2 negative form of breast cancer***.

Cancer spreading to other organs – called metastasis – is responsible for around 90 per cent of all cancer deaths. And, when patients with breast cancer are diagnosed after the disease has started to spread, 10-year survival is around one in 10, compared to nearly nine in 10 for those diagnosed at the earliest stage.

Study author, Professor Chris Twelves, said: "Our results show a substantial improvement in survival for women with metastatic triple negative breast cancer, and a more modest, but significant, benefit for those with HER2 negative breast cancers.

"Eribulin has previously been offered to women who've already been through several lines of chemotherapy. But the European Union has recently approved eribulin for patients who have received less treatment for their breast cancer, which means we hope to give more patients another treatment option in the not-too-distant future.

"Despite advances in the diagnosis and treatment of women with breast cancer, more than 11,600 women still die from invasive breast cancer each year in the UK. New and better treatments are needed for people fighting the disease."

Eribulin works by stopping the cancer cells from separating into two new cells. It is a type of drug called a microtubule inhibitor. Eribulin was originally developed from a sea sponge called Halichondria okadai but is now made in the laboratory.

Martin Ledwick, head information nurse at Cancer Research UK, said: "These results are encouraging and may offer valuable extra time to patients whose cancers have stopped responding to conventional treatments and have few options left. Advanced breast cancer can be very difficult to treat so these results take us a small, important step in the right direction.

"Although eribulin isn't a cure, it's an extra treatment option for patients with advanced breast cancer, which can be priceless to them and their families."

Read the full conference abstract - http://conference.ncri.org.uk/abstracts/2014/abstracts/A036.html

*Eribulin (also called eribulin mesylate or Halaven) is a chemotherapy drug used to treat advanced breast cancer. It is usually given to people who have already had at least two other courses of chemotherapy. Eribulin works by stopping (inhibiting) the cancer cells from separating into two new cells. It is a type of drug called a microtubule inhibitor.

** Overall survival for women treated with eribulin was 15.2 months, compared to 12.8 months for women given standard therapies. Women with HER+ breast cancer saw no statistically significant improvement.

*** HER2 stands for human epidermal growth factor receptor. It is a protein found in small amounts on some normal cells, including breast cells, stomach cells and bladder cells. It is one of the proteins involved in cell growth. Some cancers have cells with large amounts of this protein and they are called HER2 positive. These cancers can be treated with drugs that target the HER2 protein. If a cancer does not have large amounts of the HER2 protein it is called HER2 negative.

Triple negative breast cancers are cancers that don't have receptors for oestrogen, progesterone or Her2. Only around 15 out of every 100 breast cancers (15%) are triple negative.

Greg Jones | EurekAlert!
Further information:
http://www.cancer.org.uk

Further reports about: CANCER Chemotherapy HER2 breast breast cancer cancer cells microtubule sponge

More articles from Health and Medicine:

nachricht Light beam replaces blood test during heart surgery
28.02.2017 | University of Central Florida

nachricht Cells adapt ultra-rapidly to zero gravity
28.02.2017 | Universität Zürich

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

New technology offers fast peptide synthesis

28.02.2017 | Life Sciences

WSU research advances energy savings for oil, gas industries

28.02.2017 | Power and Electrical Engineering

Who can find the fish that makes the best sound?

28.02.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>